相似文献
1
Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio.
Antimicrob Agents Chemother. 1995 Nov;39(11):2591-2. doi: 10.1128/AAC.39.11.2591.
2
Beta-lactamase inhibitors and Acinetobacter spp.
J Antimicrob Chemother. 1990 Sep;26(3):449-51. doi: 10.1093/jac/26.3.449.
3
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Infection. 1991 Mar-Apr;19(2):106-9. doi: 10.1007/BF01645578.
4
Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.
Antimicrob Agents Chemother. 1994 Mar;38(3):494-8. doi: 10.1128/AAC.38.3.494.
5
In vitro susceptibility-resistance patterns of bacterial isolates from burn patients to augmentin and timentin.
J Burn Care Rehabil. 1985 Jul-Aug;6(4):331-4. doi: 10.1097/00004630-198507000-00005.
6
Antibacterial activities of amoxicillin alone and in combination with clavulanic acid correlated with beta-lactamase production.
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1991 Aug;24(3):272-80.
7
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
Antimicrob Agents Chemother. 1995 Nov;39(11):2478-83. doi: 10.1128/AAC.39.11.2478.
8
Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.
Epidemiol Infect. 1993 Feb;110(1):117-25. doi: 10.1017/s0950268800050743.
9
[The development of bacterial resistance and the role of clavulanic acid].
Antibiot Khimioter. 1992 Sep;37(9):11-4.
10
Interpretive criteria for susceptibilities of Haemophilus influenzae to ampicillin, amoxicillin, and amoxicillin-clavulanic acid.
J Clin Microbiol. 1994 Nov;32(11):2846-50. doi: 10.1128/jcm.32.11.2846-2850.1994.
引用本文的文献
1
Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis. 2024 Aug 16;79(2):516-523. doi: 10.1093/cid/ciae201.
2
What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.
Clin Lab Med. 2019 Sep;39(3):473-485. doi: 10.1016/j.cll.2019.05.006. Epub 2019 Jul 6.
3
Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2369-77. doi: 10.1007/s10096-012-1578-x. Epub 2012 Feb 27.
4
Three decades of beta-lactamase inhibitors.
Clin Microbiol Rev. 2010 Jan;23(1):160-201. doi: 10.1128/CMR.00037-09.
5
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Antimicrob Agents Chemother. 2004 May;48(5):1586-92. doi: 10.1128/AAC.48.5.1586-1592.2004.
6
Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.
Antimicrob Agents Chemother. 1999 Apr;43(4):862-7. doi: 10.1128/AAC.43.4.862.
7
Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
J Clin Microbiol. 1998 May;36(5):1361-5. doi: 10.1128/JCM.36.5.1361-1365.1998.
8
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find.
J Clin Microbiol. 1997 Oct;35(10):2593-7. doi: 10.1128/jcm.35.10.2593-2597.1997.
Zotero 插件